PFE 241220 33.00C (PFE241220C33000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

PFE241220C33000

Watchlist

0.04
0.000.00%

15min DelayTrading Dec 13 13:05 ET

0.00High0.00Low

Intraday

5D
Daily

News

Another Week, Another Index Record | Lkive Stock
Kevin Travers6minutes ago
Goldman Sachs Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $33
Moomoo News17minutes ago · Ratings
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $33
Moomoo News09:31 ET · Ratings
Jefferies Sticks to Their Buy Rating for Pfizer (PFE)
TipRanks08:45 ET · Ratings
Wells Fargo Adjusts Price Target on Pfizer to $27 From $30
MT Newswires08:13 ET · Ratings
Promise Bio Emerges From Stealth With $8.3M Seed Investment to Transform Precision Medicine for Immune-Mediated Diseases
PR Newswire03:00 ET

Comments

10xStockPicks

15 hours ago

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

17 hours ago

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

Phil Dunn

Yesterday 00:48

Weekly Trading Report (2nd Week Dec)

A quick update of my trading activities in this week (9 to 13 Dec 2024).
New Positions
$Symbotic (SYM.US)$ , $IonQ Inc (IONQ.US)$ , $Alphabet-A (GOOGL.US)$ , $PepsiCo (PEP.US)$ , $Futu Holdings Ltd (FUTU.US)$
Sold out Positions
$Hershey (HSY.US)$ , $UnitedHealth (UNH.US)$ , $Taiwan Semiconductor (TSM.US)$
Increased / Decreased Positions
None
Remarks
- I sold out $Hershey (HSY.US)$ after buyout news came out. I took decent profit from this rumour.
- Just few days after I bought $UnitedHealth (UNH.US)$ , I sold ...

Tesla hits historical high, how much room for upside?

Deep Sea

Dec 12 17:31

$Pfizer (PFE.US)$
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer.
"Our decision to increase our quarterly dividend underscores our strong fi...

Moomoo Recap US

Dec 11 15:29

Columns Nasdaq Surges Past 20,000 for the First Time, Powered by Tech Giants | Wall Street Today

The $Nasdaq Composite Index (.IXIC.US)$ hit a record intraday and closing high Wednesday, crossing 20,000 points for the first time. The index was up 1.8% at 20,050 in late trading, finishing 1.77% higher. The $S&P 500 Index (.SPX.US)$ closed just below its highest close on record at 6,090.27, while the $Dow Jones Industrial Average (.DJI.US)$ fell 0.2%.
MACRO
In economic news, November’s consumer price index (C...

Weekly Buzz